Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Goldenberg

Showing results (141-150 of 296) with videos related to

Pageof 30
Sort By:
Cancer Research|January 25, 2003
A universal pretargeting system for cancer detection and therapy using bispecific antibodyRobert M Sharkey, William J McBride, Habibe Karacay, et al.
Gynecologic Oncology Reports|July 7, 2018
Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case reportChanhee Han, Stefania Bellone, Peter E Schwartz, et al.
EJNMMI Research|September 6, 2019
A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancerFortuné M K Elekonawo, Susanne Lütje, Gerben M Franssen, et al.
Bioconjugate Chemistry|June 15, 2010
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complexWilliam J McBride, Christopher A D'Souza, Robert M Sharkey, et al.
Blood|January 27, 2010
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathwaysRhona Stein, Pankaj Gupta, Xiaochuan Chen, et al.
Cancer|October 15, 2008
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphomaJohn P Leonard, Stephen J Schuster, Christos Emmanouilides, et al.
Molecular Pharmaceutics|November 18, 2014
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drugSerengulam V Govindan, Thomas M Cardillo, Edmund A Rossi, et al.
Blood|August 7, 2004
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignanciesRhona Stein, Zhengxing Qu, Thomas M Cardillo, et al.
Arthritis Research & Therapy|July 25, 2006
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II studySerge D Steinfeld, Laure Tant, Gerd R Burmester, et al.
British Journal of Haematology|July 9, 2013
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I studyHoward A Liebman, Mansoor N Saleh, James B Bussel, et al.
Pageof 30

Showing results (141-150 of 296) with videos related to

Sort By:
Pageof 30
Cancer Research|January 25, 2003
A universal pretargeting system for cancer detection and therapy using bispecific antibodyRobert M Sharkey, William J McBride, Habibe Karacay, et al.
Gynecologic Oncology Reports|July 7, 2018
Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case reportChanhee Han, Stefania Bellone, Peter E Schwartz, et al.
EJNMMI Research|September 6, 2019
A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancerFortuné M K Elekonawo, Susanne Lütje, Gerben M Franssen, et al.
Bioconjugate Chemistry|June 15, 2010
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complexWilliam J McBride, Christopher A D'Souza, Robert M Sharkey, et al.
Blood|January 27, 2010
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathwaysRhona Stein, Pankaj Gupta, Xiaochuan Chen, et al.
Cancer|October 15, 2008
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphomaJohn P Leonard, Stephen J Schuster, Christos Emmanouilides, et al.
Molecular Pharmaceutics|November 18, 2014
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drugSerengulam V Govindan, Thomas M Cardillo, Edmund A Rossi, et al.
Blood|August 7, 2004
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignanciesRhona Stein, Zhengxing Qu, Thomas M Cardillo, et al.
Arthritis Research & Therapy|July 25, 2006
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II studySerge D Steinfeld, Laure Tant, Gerd R Burmester, et al.
British Journal of Haematology|July 9, 2013
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I studyHoward A Liebman, Mansoor N Saleh, James B Bussel, et al.
Pageof 30